Key Segmentation:
By Diagnostic Method
-
Molecular Diagnostics
-
Immunoassays
-
Rapid Diagnostic Tests
-
Vaginal pH Tests
-
Gram Stain & Microscopy
-
Other Methods
By Testing Setting
-
Laboratory-Based Testing
-
Point-of-Care Testing
By Sample Collection
-
Clinician-Collected
-
Self-Collected
By End User
-
Hospitals
-
Clinics
-
Diagnostic Laboratories
-
Other End Users
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Diagnostic Method X End User)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
Key players include Becton, Dickinson and Company, Hologic, Inc., QIAGEN N.V., Sekisui Diagnostics, and bioMérieux SA, among others.
Key opportunities include CLIA-waived point-of-care molecular testing, self-collected and at-home testing, and affordable rapid tests for high-prevalence emerging markets.
The primary growth factor is the high global prevalence of bacterial vaginosis, combined with the shift from subjective traditional methods to accurate molecular testing.
By diagnostic method, the Molecular Diagnostics segment dominates the Bacterial Vaginosis Diagnostics Market with approximately 38.64% share in 2025.
North America dominates the Bacterial Vaginosis Diagnostics Market with approximately 42.37% share in 2025.
